Thrombotic thrombocytopenic purpura in children
Authors:
- Chantal LoiratCLChantal Loirat
- Paul CoppoPCPaul Coppo
- Agnès VeyradierAVAgnès Veyradier
- 1 April 2013
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Pediatrics
- Vol. 25 (2) , 216-224
Abstract
Thrombotic thrombocytopenic purpura (TTP) is a rare life-threatening disease in children, due to a severe deficiency of ADAMTS13 (a disintegrin and metalloproteinase with thrombospondin type 1 repeats, member 13), inherited in congenital TTP or secondary to anti-ADAMTS13 antibodies in acquired TTP. Rapid techniques for ADAMTS 13 assays, long-term follow-up of patients, phenotype-genotype analysis, improved therapeutic schedules, and new therapies have emerged. Rapid techniques for ADAMTS13 assays now permit rapid confirmation of diagnosis. In congenital TTP, mutations affecting the N-terminal domains of ADAMTS13 are associated with lower residual ADAMTS13 activity and more severe phenotype. Early initiation of plasma infusion treatment and lifelong prophylactic plasma infusion have decreased mortality and sequels and prevent relapses. In acquired TTP, a disease of adolescents but also of children less than 2, adding rituximab to plasma exchange is beneficial. Recombinant ADAMTS13 ought to be soon available for congenital TTP, while acquired TTP children might benefit from its administration, alone or in association with rituximab, to avoid or limit plasma exchange duration. Progress in the understanding of TTP has boosted physicians' awareness that diagnosis and treatment are medical emergencies. New therapies hopefully will decrease treatment burden and improve prognosis.Keywords
This publication has 71 references indexed in Scilit:
- Paradigm shift of childhood thrombotic thrombocytopenic purpura with severe ADAMTS13 deficiencyLa Presse Médicale, 2012
- Atypical hemolytic uremic syndromeOrphanet Journal of Rare Diseases, 2011
- Pathophysiology of thrombotic thrombocytopenic purpuraInternational Journal of Hematology, 2010
- Thrombotic thrombocytopenic purpura related to severe ADAMTS13 deficiency in childrenPediatric Nephrology, 2009
- von Willebrand factor: two sides of a coinJournal of Thrombosis and Haemostasis, 2005
- Structure of von Willebrand Factor-cleaving Protease (ADAMTS13), a Metalloprotease Involved in Thrombotic Thrombocytopenic PurpuraJournal of Biological Chemistry, 2001
- Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpuraNature, 2001
- Upshaw-Schulman Syndrome Revisited: A Concept of Congenital Thrombotic Thrombocytopenic PurpuraInternational Journal of Hematology, 2001
- Antibodies to von Willebrand Factor–Cleaving Protease in Acute Thrombotic Thrombocytopenic PurpuraNew England Journal of Medicine, 1998
- von Willebrand Factor–Cleaving Protease in Thrombotic Thrombocytopenic Purpura and the Hemolytic–Uremic SyndromeNew England Journal of Medicine, 1998